SG10201909638UA - Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules - Google Patents
Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii moleculesInfo
- Publication number
- SG10201909638UA SG10201909638UA SG10201909638UA SG10201909638UA SG 10201909638U A SG10201909638U A SG 10201909638UA SG 10201909638U A SG10201909638U A SG 10201909638UA SG 10201909638U A SG10201909638U A SG 10201909638UA
- Authority
- SG
- Singapore
- Prior art keywords
- genetically modified
- mhc
- molecules
- major histocompatibility
- histocompatibility complex
- Prior art date
Links
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title abstract 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title abstract 5
- 241000699670 Mus sp. Species 0.000 title abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 210000002257 embryonic structure Anatomy 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552584P | 2011-10-28 | 2011-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201909638UA true SG10201909638UA (en) | 2019-11-28 |
Family
ID=47430036
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201510056SA SG10201510056SA (en) | 2011-10-28 | 2012-10-26 | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
SG10201909638U SG10201909638UA (en) | 2011-10-28 | 2012-10-26 | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
SG11201400938UA SG11201400938UA (en) | 2011-10-28 | 2012-10-26 | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201510056SA SG10201510056SA (en) | 2011-10-28 | 2012-10-26 | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201400938UA SG11201400938UA (en) | 2011-10-28 | 2012-10-26 | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
Country Status (25)
Country | Link |
---|---|
US (6) | US8847005B2 (pl) |
EP (4) | EP3272214B1 (pl) |
JP (2) | JP6285361B2 (pl) |
KR (2) | KR102113108B1 (pl) |
CN (3) | CN108707608A (pl) |
AU (4) | AU2012327205B2 (pl) |
BR (1) | BR112014009941B1 (pl) |
CA (1) | CA2852962C (pl) |
CY (2) | CY1119283T1 (pl) |
DK (3) | DK3590332T3 (pl) |
ES (3) | ES2640241T3 (pl) |
HK (2) | HK1196999A1 (pl) |
HR (3) | HRP20220616T1 (pl) |
HU (2) | HUE048511T2 (pl) |
IL (3) | IL231895B (pl) |
IN (1) | IN2014CN03892A (pl) |
LT (3) | LT3272214T (pl) |
MX (1) | MX355726B (pl) |
PL (3) | PL2770822T3 (pl) |
PT (3) | PT2770822T (pl) |
RS (3) | RS56330B1 (pl) |
RU (1) | RU2660564C2 (pl) |
SG (3) | SG10201510056SA (pl) |
SI (3) | SI3590332T1 (pl) |
WO (1) | WO2013063340A1 (pl) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008054865A2 (en) | 2006-04-26 | 2008-05-08 | L-3 Communications Security And Detection Systems, Inc. | Multi-source surveillance systems |
PL2818478T3 (pl) | 2011-10-28 | 2017-09-29 | Regeneron Pharmaceuticals, Inc. | Humanizowane il-6 i receptor il-6 |
ES2640241T3 (es) | 2011-10-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Ratones modificados genéticamente que expresan moléculas quiméricas del complejo de histocompatibilidad mayor (MHC) de clase II |
US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
EP2958938B1 (en) | 2013-02-20 | 2019-04-17 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
JP6444321B2 (ja) | 2013-02-22 | 2018-12-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | ヒト化主要組織適合性遺伝子複合体を発現するマウス |
US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
EP2967015B9 (en) | 2013-03-11 | 2023-08-09 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
CN108441497B (zh) | 2013-09-23 | 2021-10-29 | 瑞泽恩制药公司 | 具有人源化信号调节蛋白基因的非人动物 |
SI3138397T1 (sl) * | 2013-10-15 | 2019-04-30 | Regeneron Pharmaceuticals, Inc. | Humanizirane živali IL-15 |
CA2929846C (en) | 2013-11-19 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
EP3129400B1 (en) | 2014-04-08 | 2020-03-25 | Regeneron Pharmaceuticals, Inc. | Non-human animals having humanized fc-gamma receptors |
NO2785538T3 (pl) | 2014-05-07 | 2018-08-04 | ||
PL3157956T3 (pl) * | 2014-06-19 | 2020-06-29 | Regeneron Pharmaceuticals, Inc. | Zwierzęta inne niż człowiek mające humanizowany gen zaprogramowanej śmierci komórkowej 1 |
BR112017005245A2 (pt) | 2014-09-19 | 2017-12-12 | Regeneron Pharma | animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos. |
HUE059417T2 (hu) | 2014-11-24 | 2022-11-28 | Regeneron Pharma | Humanizált CD3-komplexet expresszáló nem humán állatok |
SI3850946T1 (sl) | 2014-12-05 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Nehumane živali, ki imajo humaniziran grozd diferenciacije gena 47 |
KR102316842B1 (ko) | 2014-12-09 | 2021-10-25 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 분화 클러스터 274 유전자를 갖는 비인간 동물 |
PL3280257T3 (pl) | 2015-04-06 | 2023-10-23 | Regeneron Pharmaceuticals, Inc. | Odpowiedzi odpornościowe za pośrednictwem humanizowanych komórek t u zwierząt innych niż człowiek |
SI3376857T1 (sl) | 2015-11-20 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Nehumane živali, ki imajo humaniziran gen 3 za aktivacijo limfocitov |
EP3411392B1 (en) * | 2016-02-04 | 2021-12-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered angptl8 gene |
EP3422845B1 (en) | 2016-02-29 | 2021-06-02 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized tmprss gene |
AU2017272337C1 (en) | 2016-06-03 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化trkb遺伝子座を含む非ヒト動物 |
EP3772927A1 (en) | 2018-03-24 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
KR20210004994A (ko) | 2018-03-26 | 2021-01-13 | 리제너론 파마슈티칼스 인코포레이티드 | 치료제를 시험하기 위한 인간화된 설치류 |
LT3823443T (lt) | 2018-07-16 | 2024-08-12 | Regeneron Pharmaceuticals, Inc. | Ditra ligos graužikų modeliai ir jų naudojimas |
CN114585744A (zh) * | 2019-10-22 | 2022-06-03 | 纽约市哥伦比亚大学理事会 | 转基因猪、其制造方法和用途以及制造人免疫系统小鼠的方法 |
US20220409732A1 (en) | 2019-12-02 | 2022-12-29 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
US20220322648A1 (en) | 2021-03-31 | 2022-10-13 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrb repertoire |
WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
WO2024064860A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing components of human cellular immune system |
WO2024159071A1 (en) | 2023-01-27 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Modified rhabdovirus glycoproteins and uses thereof |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU633958B2 (en) | 1989-07-25 | 1993-02-11 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
AU2661692A (en) | 1991-09-19 | 1993-04-27 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | TRANSGENIC NON-HUMAN ANIMALS WITH TARGETED INTERRUPTED TRANSDUCTION GENES IN LYMPHOCYTES. |
US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
CA2246333A1 (en) | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
PT1500329E (pt) | 1996-12-03 | 2012-06-18 | Amgen Fremont Inc | Anticorpos humanos que se ligam especificamente ao tnf alfa humano |
CA2302779C (en) | 1997-09-16 | 2010-02-02 | Oregon Health Sciences University | Recombinant mhc molecules useful for manipulation of antigen-specific t-cells |
US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
CN1161614C (zh) * | 1998-03-30 | 2004-08-11 | 研究发展基金会 | 用促肾上腺皮质素释放因子受体-1缺陷型小鼠鉴定促效剂和拮抗剂的方法 |
AU1023401A (en) | 1999-10-12 | 2001-04-23 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
US7067308B1 (en) * | 2000-03-28 | 2006-06-27 | Bioagri Corporation | Vector for genetically modifying non-human animals |
WO2002000933A2 (en) | 2000-06-23 | 2002-01-03 | Interleukin Genetics, Inc. | Screening assays for identifying modulators of the inflammatory or immune responses |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20050050580A1 (en) | 2000-12-13 | 2005-03-03 | Masashi Gotoh | Transgenic animal expressing hla-a24 and utilization thereof |
DK1409646T3 (da) | 2000-12-19 | 2012-08-06 | Altor Bioscience Corp | Transgene dyr omfattende et humaniseret immunsystem |
FR2827302B1 (fr) | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
US20040072262A1 (en) | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
US7663017B2 (en) | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
WO2005085438A1 (ja) | 2004-03-09 | 2005-09-15 | Nagoya Industrial Science Research Institute | ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物 |
EP2767161B1 (en) | 2004-10-19 | 2018-02-07 | Regeneron Pharmaceuticals, Inc. | Method for generating an non-human animal homozygous for a genetic modification |
EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
HU0700534D0 (en) | 2006-11-24 | 2007-10-29 | Mezoegazdasagi Biotechnologiai | Transgenic animal with enhanced immune response and method for the preparation thereof |
NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
TWI476280B (zh) | 2008-03-07 | 2015-03-11 | Regeneron Pharma | 來自二倍體宿主胚胎注射之es-細胞衍生的老鼠 |
US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
PT2421357E (pt) | 2009-07-08 | 2013-04-18 | Kymab Ltd | Modelos animais e moléculas terapêuticas |
CN101695587B (zh) * | 2009-10-21 | 2012-08-29 | 上海中山医疗科技发展公司 | 一种基因修饰及调控的内皮祖细胞捕获支架的制备方法 |
WO2012007951A1 (en) | 2010-07-15 | 2012-01-19 | Technion Research & Development Foundation Ltd. | Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides |
US9557323B2 (en) | 2010-09-24 | 2017-01-31 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
ES2640241T3 (es) | 2011-10-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Ratones modificados genéticamente que expresan moléculas quiméricas del complejo de histocompatibilidad mayor (MHC) de clase II |
EP2958938B1 (en) | 2013-02-20 | 2019-04-17 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
JP6444321B2 (ja) | 2013-02-22 | 2018-12-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | ヒト化主要組織適合性遺伝子複合体を発現するマウス |
EP2967015B9 (en) | 2013-03-11 | 2023-08-09 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
PL3280257T3 (pl) | 2015-04-06 | 2023-10-23 | Regeneron Pharmaceuticals, Inc. | Odpowiedzi odpornościowe za pośrednictwem humanizowanych komórek t u zwierząt innych niż człowiek |
-
2012
- 2012-10-26 ES ES12806199.1T patent/ES2640241T3/es active Active
- 2012-10-26 ES ES19189533T patent/ES2914374T3/es active Active
- 2012-10-26 RU RU2014116577A patent/RU2660564C2/ru active
- 2012-10-26 KR KR1020187034955A patent/KR102113108B1/ko active IP Right Grant
- 2012-10-26 CA CA2852962A patent/CA2852962C/en active Active
- 2012-10-26 PL PL12806199T patent/PL2770822T3/pl unknown
- 2012-10-26 IN IN3892CHN2014 patent/IN2014CN03892A/en unknown
- 2012-10-26 PT PT128061991T patent/PT2770822T/pt unknown
- 2012-10-26 US US13/661,116 patent/US8847005B2/en active Active
- 2012-10-26 EP EP17171524.6A patent/EP3272214B1/en active Active
- 2012-10-26 ES ES17171524T patent/ES2774488T3/es active Active
- 2012-10-26 PL PL17171524T patent/PL3272214T3/pl unknown
- 2012-10-26 LT LTEP17171524.6T patent/LT3272214T/lt unknown
- 2012-10-26 DK DK19189533.3T patent/DK3590332T3/da active
- 2012-10-26 RS RS20170897A patent/RS56330B1/sr unknown
- 2012-10-26 RS RS20200224A patent/RS59997B1/sr unknown
- 2012-10-26 HU HUE17171524A patent/HUE048511T2/hu unknown
- 2012-10-26 PT PT171715246T patent/PT3272214T/pt unknown
- 2012-10-26 DK DK12806199.1T patent/DK2770822T3/en active
- 2012-10-26 JP JP2014539027A patent/JP6285361B2/ja active Active
- 2012-10-26 WO PCT/US2012/062029 patent/WO2013063340A1/en active Application Filing
- 2012-10-26 EP EP12806199.1A patent/EP2770822B9/en active Active
- 2012-10-26 CN CN201810239690.4A patent/CN108707608A/zh active Pending
- 2012-10-26 MX MX2014004896A patent/MX355726B/es active IP Right Grant
- 2012-10-26 AU AU2012327205A patent/AU2012327205B2/en active Active
- 2012-10-26 SI SI201231999T patent/SI3590332T1/sl unknown
- 2012-10-26 LT LTEP12806199.1T patent/LT2770822T/lt unknown
- 2012-10-26 DK DK17171524.6T patent/DK3272214T3/da active
- 2012-10-26 LT LTEP19189533.3T patent/LT3590332T/lt unknown
- 2012-10-26 CN CN201810239986.6A patent/CN108401986B/zh active Active
- 2012-10-26 RS RS20220473A patent/RS63220B1/sr unknown
- 2012-10-26 SI SI201231056T patent/SI2770822T1/sl unknown
- 2012-10-26 SG SG10201510056SA patent/SG10201510056SA/en unknown
- 2012-10-26 CN CN201280065075.7A patent/CN104039133B/zh active Active
- 2012-10-26 SG SG10201909638U patent/SG10201909638UA/en unknown
- 2012-10-26 KR KR1020147014315A patent/KR101926442B1/ko active IP Right Grant
- 2012-10-26 EP EP19189533.3A patent/EP3590332B1/en active Active
- 2012-10-26 HR HRP20220616TT patent/HRP20220616T1/hr unknown
- 2012-10-26 PT PT191895333T patent/PT3590332T/pt unknown
- 2012-10-26 EP EP22152099.2A patent/EP4052572A1/en active Pending
- 2012-10-26 BR BR112014009941-3A patent/BR112014009941B1/pt active IP Right Grant
- 2012-10-26 SG SG11201400938UA patent/SG11201400938UA/en unknown
- 2012-10-26 SI SI201231738T patent/SI3272214T1/sl unknown
- 2012-10-26 PL PL19189533T patent/PL3590332T3/pl unknown
- 2012-10-26 HU HUE12806199A patent/HUE034374T2/en unknown
-
2014
- 2014-04-03 IL IL231895A patent/IL231895B/en active IP Right Grant
- 2014-08-08 US US14/455,237 patent/US9585373B2/en active Active
- 2014-10-23 HK HK14110588.1A patent/HK1196999A1/xx unknown
-
2016
- 2016-01-11 IL IL243565A patent/IL243565A/en active IP Right Grant
- 2016-04-13 AU AU2016202317A patent/AU2016202317B2/en active Active
-
2017
- 2017-01-24 US US15/413,785 patent/US10219493B2/en active Active
- 2017-08-17 JP JP2017157497A patent/JP6652529B2/ja active Active
- 2017-09-04 HR HRP20171327TT patent/HRP20171327T1/hr unknown
- 2017-09-05 CY CY20171100934T patent/CY1119283T1/el unknown
-
2018
- 2018-02-27 AU AU2018201402A patent/AU2018201402C1/en active Active
- 2018-06-21 IL IL260209A patent/IL260209B/en active IP Right Grant
- 2018-07-24 HK HK18109591.4A patent/HK1250131A1/zh unknown
-
2019
- 2019-01-10 US US16/244,912 patent/US10986822B2/en active Active
- 2019-01-10 US US16/244,892 patent/US11219195B2/en active Active
-
2020
- 2020-02-24 HR HRP20200305TT patent/HRP20200305T1/hr unknown
- 2020-02-26 CY CY20201100178T patent/CY1122700T1/el unknown
-
2021
- 2021-01-22 AU AU2021200438A patent/AU2021200438B2/en active Active
- 2021-03-17 US US17/204,526 patent/US20210195878A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201909638UA (en) | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules | |
MY178723A (en) | Genetically modified major histocompatibility complex mice | |
CY1121979T1 (el) | Ποντικια που εκφραζουν ανθρωποποιημενους τ-λεμφοκυτταρικους συνυποδοχεις | |
EP4249507A3 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules | |
CY1121223T1 (el) | Ποντικοι οι οποιοι εκφραζουν ανθρωποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας | |
MX2020007021A (es) | Receptor quimerico de antigeno anti-cd19 humanizado. | |
AU2013312359A8 (en) | Genetically modified non-human animals and methods of use thereof | |
EP4269430A3 (en) | Non-human animals having a humanized signal-regulatory protein gene | |
MY175954A (en) | Light-sensitive ion-passing molecules | |
MX353134B (es) | Ratones con receptor de linfocitos t modificados geneticamente. | |
EA201592269A1 (ru) | Способы и композиции для снижения иммуносупрессии опухолевыми клетками | |
BR112017010793A2 (pt) | animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo. | |
MX2014015679A (es) | Roedores con il-7 humanizada. | |
EP2531207A4 (en) | METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY USING TUMOR CELLS EXPRESSING TUMOR ANTIGEN / FLAGELLIN HYBRID PROTEIN | |
MX2021000586A (es) | Ratones transgenicos que expresan moleculas quimericas del complejo mayor de histocompatibilidad (cmh) clase ii. | |
NZ621320A (en) | Anti-human xcr1 antibodies |